Literature DB >> 24393783

Pharmacotherapy: a new option for Cushing disease?

Vicky Heath.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24393783     DOI： 10.1038/nrendo.2013.266

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  1 in total

1.  LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.

Authors:  Xavier Bertagna; Rosario Pivonello; Maria Fleseriu; Yiming Zhang; Paul Robinson; Ann Taylor; Catherine E Watson; Mario Maldonado; Amir H Hamrahian; Marco Boscaro; Beverly M K Biller
Journal:  J Clin Endocrinol Metab       Date:  2013-12-11       Impact factor: 5.958
  1 in total
  1 in total

1.  Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2).

Authors:  Katrijn Bogman; Dietmar Schwab; Marie-Laure Delporte; Giuseppe Palermo; Kurt Amrein; Susanne Mohr; Maria Cristina De Vera Mudry; Morris J Brown; Philippe Ferber
Journal:  Hypertension       Date:  2016-11-21       Impact factor: 10.190
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.